Piramal Pharma is undergoing an important business transformation. The Indian pharmaceutical company is expanding its position in global drug development, complex hospital medicines and consumer healthcare, creating a diversified platform that operates far beyond India’s traditional generic drug market.
While many pharmaceutical companies depend heavily on selling their own medicines, Piramal Pharma has built a different business model. It helps international pharmaceutical companies develop and manufacture drugs, supplies specialised medicines to hospitals and sells established healthcare brands directly to consumers.
With 17 development and manufacturing facilities and a distribution network spanning more than 100 countries, the company is positioning itself to benefit from pharmaceutical outsourcing, specialised treatments and growing healthcare consumption.
The central question is whether Piramal Pharma can convert its global manufacturing capabilities and specialised product portfolio into consistent, profitable growth.
How Piramal Pharma Makes Money
Piramal Pharma operates through three principal businesses: Piramal Pharma Solutions, Piramal Critical Care and Piramal Consumer Healthcare.
Piramal Pharma Solutions provides contract development and manufacturing services to pharmaceutical and biotechnology companies. Piramal Critical Care supplies complex medicines used in hospitals, while Piramal Consumer Healthcare markets over-the-counter products and wellness brands.
These businesses have different commercial characteristics. Contract manufacturing depends on customer projects and manufacturing contracts, hospital generics benefit from specialised production capabilities, and consumer healthcare relies on brands, distribution and repeat purchases.
This structure gives Piramal Pharma exposure to multiple healthcare markets, although each business faces its own competitive and operational challenges.
Also Read: PC Jeweller: From Debt Crisis to a Debt-Free Jewellery Retailer — Can Its Next Expansion Deliver?
Piramal Pharma Solutions: The Global CDMO Opportunity
Piramal Pharma Solutions is the company’s largest business and one of its most important long-term growth opportunities.
As a contract development and manufacturing organisation, or CDMO, it supports pharmaceutical companies from early-stage drug development through commercial manufacturing.
Developing new medicines requires specialised infrastructure, scientific expertise and regulatory compliance. Rather than building every capability internally, pharmaceutical and biotechnology companies increasingly use external manufacturing partners for selected stages of drug development and production.
Piramal Pharma serves more than 500 global customers through its CDMO platform.
Also Read: Vodafone Idea: Can India’s Telecom Challenger Turn Its 5G Expansion Into a Business Comeback?
Its capabilities include active pharmaceutical ingredients, highly potent compounds, antibody-drug conjugates, sterile injectables and drug products.
These specialised manufacturing categories are strategically important because they often involve complex processes, significant technical investment and demanding quality standards.
The company has committed approximately $90 million to expanding sterile injectable and payload-linker capabilities at its Lexington and Riverview facilities in the United States.
Successful execution could strengthen Piramal Pharma’s position in higher-value pharmaceutical manufacturing, particularly as drug developers seek specialised production partners.
However, the CDMO business remains sensitive to biotechnology funding, customer project timelines, regulatory approvals and manufacturing utilisation.
Piramal Critical Care: A Specialised Hospital Medicines Business
Piramal Critical Care operates in a different part of the pharmaceutical industry.
The business supplies complex hospital medicines, including inhalation anaesthesia products, intrathecal therapies and injectable treatments.
These products are used in specialised clinical settings where manufacturing reliability, regulatory compliance and consistent supply are essential.
Piramal Pharma has established a strong position in inhalation anaesthesia, including sevoflurane, and serves thousands of hospitals, surgical centres and clinics internationally.
Its specialised manufacturing capabilities create competitive barriers that can be more demanding than those associated with conventional oral generic medicines.
The company has also expanded this business through the acquisition of Kenalog, a complex injectable corticosteroid brand.
The transaction broadens its hospital medicines portfolio and international commercial reach.
Also Read: Delhivery Business Analysis: How India’s Technology-Driven Logistics Company Makes Money
For Piramal Pharma, the opportunity lies in expanding specialised product offerings while maintaining supply reliability and controlling manufacturing costs.
Consumer Healthcare: Building Brands Beyond Prescription Medicines
Piramal Consumer Healthcare provides the company with direct exposure to Indian households.
Its portfolio includes brands such as Lacto Calamine, Little’s, i-range and other established consumer healthcare products.
Unlike the CDMO business, which primarily serves pharmaceutical companies, consumer healthcare depends on retail distribution, brand recognition, advertising and consumer purchasing behaviour.
Also Read: VRL Logistics: Inside India’s Road Transport Giant and Its Expanding Logistics Business
Piramal Pharma has increasingly focused on developing a smaller number of stronger brands rather than relying solely on a broad collection of products.
Its Power Brands contributed 53% of consumer healthcare sales during the first half of FY2026–27, with revenue from these brands growing 21% year over year.
E-commerce is becoming another important distribution channel. Online sales grew 32% during the same period and represented 28% of the consumer healthcare business.
This shift gives Piramal Pharma opportunities to reach younger consumers through digital platforms, premium skincare and wellness products.
Also Read: ITC Farm-to-Food Business Model: Sourcing, Brands and Cash Flow
Nevertheless, consumer healthcare remains competitive, requiring sustained marketing expenditure and successful product innovation.
Why Global Manufacturing Matters
Piramal Pharma’s international manufacturing footprint is central to its competitive position.
The company operates facilities across multiple geographies and serves customers in regulated pharmaceutical markets.
Approximately 66% of its FY2025–26 revenue came from regulated markets, highlighting its exposure to regions with demanding quality and compliance requirements.
Also Read: ServiceNow: From IT Ticketing to the AI Agent Operating System for Enterprises
Geographical diversification can help pharmaceutical customers manage supply-chain risks and select manufacturing locations based on technical capability, regulation and commercial considerations.
Piramal Pharma’s established facilities also provide opportunities to expand existing customer relationships without building entirely new manufacturing networks.
However, operating globally introduces currency exposure, regulatory complexity, higher compliance costs and the need for continuous investment in manufacturing standards.
Financial Performance Shows Improving Momentum
| September 2026 quarter | Latest | Change / year-ago |
|---|---|---|
| Revenue from operations | ₹2,617 crore | +28% (₹2,044 crore a year ago) |
| CDMO revenue | ₹1,424 crore | +36% |
| Complex Hospital Generics revenue | ₹849 crore | +32% |
| Consumer Healthcare revenue | ₹359 crore | +13% |
| Consolidated EBITDA | ₹385 crore | +72% |
| EBITDA margin | 14.7% | 11.0% a year ago |
| Net profit | ₹5 crore (approx.) | Loss of ₹99 crore a year ago |
| FY2026–27 revenue growth outlook | 19–20% | Raised by management |
Piramal Pharma’s latest September 2026 quarter demonstrated stronger operating performance across its businesses.
Also Read: Eternal: From Zomato to a Multi-Business Consumer Platform Built Around Blinkit
Consolidated revenue from operations increased 28% year over year to ₹2,617 crore, compared with ₹2,044 crore in the corresponding quarter.
The CDMO business recorded revenue of ₹1,424 crore, representing 36% growth. Complex Hospital Generics revenue increased 32% to ₹849 crore, while Consumer Healthcare revenue rose 13% to ₹359 crore.
Consolidated EBITDA increased 72% to ₹385 crore, with the EBITDA margin improving to 14.7% from 11.0%.
The company reported a quarterly net profit of approximately ₹5 crore, compared with a loss of ₹99 crore a year earlier.
Also Read: Policybazaar: From Insurance Comparison Website to India’s Digital Insurance Distribution Powerhouse
Although profitability improved, the relatively modest net profit highlights the importance of depreciation, financing costs and other expenses in a capital-intensive pharmaceutical business.
Following its first-half performance, management raised its FY2026–27 revenue growth outlook to 19–20%, alongside expectations of stronger profitability.
The Biggest Opportunities and Risks
Piramal Pharma’s future growth depends on its ability to scale specialised pharmaceutical manufacturing while improving operating efficiency.
Demand for complex drug development services, antibody-drug conjugates and sterile injectables could create opportunities for its CDMO business. Meanwhile, hospital generics offer exposure to specialised therapies, and consumer healthcare provides a separate route to growth through brands and digital distribution.
Also Read: Raymond: From Suits to High-Precision Engineering — The Transformation Is Just Beginning
The risks are equally important.
Drug development projects can be delayed or cancelled, manufacturing facilities require regulatory compliance, and capacity expansion may take time to generate adequate returns. Competition, pricing pressure, customer concentration and working-capital requirements can also affect performance.
The company must balance investment in advanced manufacturing with consistent cash generation and financial discipline.
Can Piramal Pharma Build a Stronger Global Healthcare Platform?
Piramal Pharma’s business transformation is about more than increasing pharmaceutical sales. It is about building a global healthcare platform combining scientific expertise, specialised manufacturing and consumer brands.
Also Read: DMCC Speciality Chemicals: The 100-Year Chemical Company Building a New Specialty Business
Its CDMO operations offer access to international drug development spending, Critical Care provides a portfolio of complex hospital medicines, and Consumer Healthcare connects the company with India’s expanding wellness market.
The latest operating improvement suggests that higher manufacturing utilisation and stronger execution can support profitability. But sustaining that progress will require reliable customer demand, disciplined capital allocation and consistent regulatory performance.
Piramal Pharma’s long-term opportunity is to become a more profitable, specialised global pharmaceutical platform rather than simply a larger drug manufacturer.
Whether that ambition succeeds will depend on how effectively the company converts its manufacturing capabilities, international relationships and consumer brands into durable earnings and cash flow.
Also Read: Avalon Technologies: The EMS Company Quietly Building India’s Next Manufacturing Engine
Financial Disclaimer:: This article is intended for educational and informational purposes only. It does not constitute investment advice, a recommendation to buy or sell securities, or a guarantee of future returns. Investors should conduct independent research and assess their financial objectives and risk tolerance before making investment decisions. Onetrader is not a SEBI-registered investment adviser or research analyst.
Keep learning with OneTrader
Explore structured lessons and practical guides to build your market knowledge.
